Literature DB >> 11478930

Spinal N-acetyl-alpha-linked acidic dipeptidase (NAALADase) inhibition attenuates mechanical allodynia induced by paw carrageenan injection in the rat.

T Yamamoto1, N Nozaki-Taguchi, Y Sakashita.   

Abstract

N-Acetylated-alpha-linked acidic dipeptidase (NAALADase) hydrolyzes N-acetyl-aspartyl-glutamate (NAAG) to liberate N-acetyl-aspartate and glutamate. NAAG is a putative neurotransmitter and acts as a mixed agonist/antagonist on N-methyl-D-aspartate (NMDA) receptors and acts as an agonist on the metabotropic glutamate receptor 3 (mGluR3). In the present study, we examined the role of spinal NAALADase in the maintenance of mechanical allodynia induced by carrageenan injection, skin incision and mild thermal injury using 2-(phosphonomethyl)pentanedioic acid (2-PMPA), a specific NAALADase inhibitor, in rats. Mechanical allodynia was induced by injection of 2 mg carrageenan into the paw (carrageenan model), by creating a 1-cm longitudinal skin incision of the plantar aspect of the foot (post-operative model), or by application of thermal stimulation (52.5 degrees C) for 45 s to the hind paw (mild thermal injury model). 2-PMPA was administered intrathecally at the time when the maximum mechanical allodynia occurred. Mechanical allodynia was assessed by the measurement of mechanical threshold using von Frey filaments. The mechanical threshold was measured 5, 15, 30, 60 and 90 min after the drug administration. In the carrageenan model, 100 microg of 2-PMPA attenuated the level of mechanical allodynia. 2-PMPA had no effect on the level of mechanical allodynia in both the post-operative pain model and the mild thermal injury model. These data suggested that the inhibition of spinal NAALADase alleviated mechanical allodynia induced by paw carrageenan injection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11478930     DOI: 10.1016/s0006-8993(01)02650-6

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  19 in total

Review 1.  Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer.

Authors:  C Bařinka; C Rojas; B Slusher; M Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

2.  Bioanalytical method for evaluating the pharmacokinetics of the GCP-II inhibitor 2-phosphonomethyl pentanedioic acid (2-PMPA).

Authors:  Rana Rais; Camilo Rojas; Krystyna Wozniak; Ying Wu; Ming Zhao; Takashi Tsukamoto; Michelle A Rudek; Barbara S Slusher
Journal:  J Pharm Biomed Anal       Date:  2013-08-30       Impact factor: 3.935

Review 3.  Advances in understanding the peptide neurotransmitter NAAG and appearance of a new member of the NAAG neuropeptide family.

Authors:  Joseph H Neale; Rafal T Olszewski; Daiying Zuo; Karolina J Janczura; Caterina P Profaci; Kaleen M Lavin; John C Madore; Tomasz Bzdega
Journal:  J Neurochem       Date:  2011-07-01       Impact factor: 5.372

4.  FOLH1/GCPII is elevated in IBD patients, and its inhibition ameliorates murine IBD abnormalities.

Authors:  Rana Rais; Weiwei Jiang; Huihong Zhai; Krystyna M Wozniak; Marigo Stathis; Kristen R Hollinger; Ajit G Thomas; Camilo Rojas; James J Vornov; Michael Marohn; Xuhang Li; Barbara S Slusher
Journal:  JCI Insight       Date:  2016-08-04

Review 5.  Metabotropic glutamate receptors as targets for analgesia: antagonism, activation, and allosteric modulation.

Authors:  Michael C Montana; Robert W Gereau
Journal:  Curr Pharm Biotechnol       Date:  2011-10       Impact factor: 2.837

6.  Group II mGluR agonist LY354740 and NAAG peptidase inhibitor effects on prepulse inhibition in PCP and D-amphetamine models of schizophrenia.

Authors:  Caterina P Profaci; Kristyn A Krolikowski; Rafal T Olszewski; Joseph H Neale
Journal:  Psychopharmacology (Berl)       Date:  2011-02-16       Impact factor: 4.530

Review 7.  The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.

Authors:  James C Evans; Meenakshi Malhotra; John F Cryan; Caitriona M O'Driscoll
Journal:  Br J Pharmacol       Date:  2016-09-23       Impact factor: 8.739

8.  Pharmacokinetics and pharmacodynamics of the glutamate carboxypeptidase II inhibitor 2-MPPA show prolonged alleviation of neuropathic pain through an indirect mechanism.

Authors:  James J Vornov; Krystyna M Wozniak; Ying Wu; Camilo Rojas; Rana Rais; Barbara S Slusher
Journal:  J Pharmacol Exp Ther       Date:  2013-06-17       Impact factor: 4.030

9.  Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer.

Authors:  Jeroen R Mesters; Cyril Barinka; Weixing Li; Takashi Tsukamoto; Pavel Majer; Barbara S Slusher; Jan Konvalinka; Rolf Hilgenfeld
Journal:  EMBO J       Date:  2006-02-09       Impact factor: 11.598

10.  Reversible disulfide formation of the glutamate carboxypeptidase II inhibitor E2072 results in prolonged systemic exposures in vivo.

Authors:  Rana Rais; Randall Hoover; Krystyna Wozniak; Michelle A Rudek; Takashi Tsukamoto; Jesse Alt; Camilo Rojas; Barbara S Slusher
Journal:  Drug Metab Dispos       Date:  2012-09-04       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.